AMGN vs. MEDP: Amgen vs. Medpace Stock Comparison

November 11, 2026

How do Amgen (AMGN) and Medpace (MEDP) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Medpace (MEDP) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while MEDP is classified in Life Sciences Tools & Services.

Company profile comparison for Amgen (AMGN) and Medpace (MEDP)
Profile Item	AMGN	MEDP
Name	Amgen Inc. Common Stock	Medpace Holdings, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	249.05 billion USD	18.27 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	June 17, 1983	August 11, 2016
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AMGN

MEDP

GSPC

Amgen (AMGN) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Amgen (AMGN) and Medpace (MEDP). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Amgen (AMGN) and Medpace (MEDP). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Medpace (MEDP)
Metric	AMGN	MEDP
Total Return (1Y)	48.82%	13.29%
Total Return (3Y, Annualized)	24.31%	35.26%
Total Return (5Y, Annualized)	20.67%	24.49%

Risk Profile

Drawdown History

AMGN

MEDP

GSPC

Amgen (AMGN) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Amgen (AMGN) and Medpace (MEDP). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Medpace (MEDP)
Metric	AMGN	MEDP
Volatility (1Y, Annualized)	29.12%	44.16%
Beta (5Y)	0.43	1.10
Max Drawdown (5Y)	-24.86%	-42.87%
Avg. Volume (3M)	2.76M	258.39K

Risk-Adjusted Performance

Risk-Return Positioning

AMGN and MEDP are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Medpace (MEDP)
Metric	AMGN	MEDP
Sharpe Ratio (1Y)	1.53	0.20
Sortino Ratio (1Y)	2.36	0.26

Profitability

ROE (TTM)

Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Amgen (AMGN) at 78.35% also sits in the top quartile.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max: 109.18%
AMGN: 78.35%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP: 117.88%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Amgen (AMGN) at 24.14% and Medpace (MEDP) at 18.24% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN: 24.14%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP: 18.24%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and Medpace (MEDP) at 23.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max: 83.12%
AMGN: 35.79%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max: 83.12%
MEDP: 23.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Medpace (MEDP)
Metric	AMGN	MEDP
ROE (TTM)	78.35%	117.88%
ROA (TTM)	8.91%	18.71%
Net Margin (TTM)	24.14%	18.24%
Operating Margin (TTM)	35.79%	23.12%
Gross Margin (TTM)	72.47%	72.24%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and Medpace (MEDP) at 19.97% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their Revenue Growth across different time periods.

EPS Growth

Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while Medpace (MEDP) at 20.98% is closer to the peer norm — faster per-share earnings growth for AMGN.

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Medpace (MEDP)
Metric	AMGN	MEDP
Revenue Growth (YoY)	9.95%	19.97%
Revenue Growth (3Y CAGR)	11.77%	20.12%
EPS Growth (YoY)	88.23%	20.98%
EPS Growth (3Y CAGR)	5.52%	28.04%

Financial Strength

Current Ratio (MRQ)

Both Amgen (AMGN) at 1.48 and Medpace (MEDP) at 0.83 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AMGN: 1.48
Min: 0.10

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MEDP: 0.83
Min: 0.10

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Medpace (MEDP) at 0.29 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 3.76 sits above its benchmark range, pointing to a heavier debt load relative to equity.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN: 3.76
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max: 1.42
Q3: 0.65
MEDP: 0.29
Median: 0.15
Q1: 0.02
Min: 0.00

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Medpace (MEDP)
Metric	AMGN	MEDP
Current Ratio (MRQ)	1.48	0.83
Debt / Equity (MRQ)	3.76	0.29
Net Debt / EBITDA	2.31	-0.84

Dividends

Dividend Yield (TTM)

Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN: 2.16%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN: 57.62%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Medpace (MEDP)
Metric	AMGN	MEDP
Dividend Yield (TTM)	2.16%	0.00%
Dividend Payout Ratio (TTM)	57.62%	0.00%

Valuation

P/E Ratio (TTM)

Both Amgen (AMGN) at 26.69 and Medpace (MEDP) at 36.26 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max: 85.34
Q3: 43.46
AMGN: 26.69
Median: 26.69
Q1: 13.30
Min: 0.07

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max: 85.34
Q3: 43.46
MEDP: 36.26
Median: 26.69
Q1: 13.30
Min: 0.07

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and Medpace (MEDP) at 6.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max: 58.18
Q3: 25.77
Median: 7.30
AMGN: 6.40
Q1: 3.01
Min: 0.01

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max: 58.18
Q3: 25.77
Median: 7.30
MEDP: 6.44
Q1: 3.01
Min: 0.01

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Amgen (AMGN) at 17.35 and Medpace (MEDP) at 31.23 look expensive — each P/B ratio sits above its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN: 17.35
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP: 31.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Amgen (AMGN) vs. Medpace (MEDP): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Medpace (MEDP)
Metric	AMGN	MEDP
P/E Ratio (TTM)	26.69	36.26
P/S Ratio (TTM)	6.40	6.44
P/B Ratio (MRQ)	17.35	31.23
Free Cash Flow Yield (TTM)	2.96%	2.72%